Skip to main content

Dr. Kristopher P. Wentzel, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

1200 N State St, Ct-a7d
Los Angeles, CA 90033

Who else practices at this address →

Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas

Call (323) 226-7556

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2012
Medicare patients seen, 2024
346

Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Medical school: University of Miami, Lm Miller School of Medicine
  • 2012Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CA license A128813 (first issued 2014; current)
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
346
Services billed
120,881
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, ferric carboxymaltose, 1 mg21,75015
Injection, epoetin alfa, (for non-esrd use), 1000 units10,25015
Injection, denosumab, 1 mg5,64032
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count1,341245
Blood test, comprehensive group of blood chemicals1,215247
Lactate dehydrogenase (enzyme) level1,119230
Phosphate level1,115229
Uric acid level, blood1,113228
Established patient office or other outpatient visit, 30-39 minutes1,077237
Insertion of needle into vein for collection of blood sample1,039210

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $20.39 in total to this clinician.

By company
Array Biopharma Inc$20.39
By type
Food and Beverage$20.39

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $875,889 in research payments for these studies, mostly to the institutions running them.

  • An open-label phase 1,2A study of GV20-0251 monotherapy and GV20-0251 in combination with pembrolizumab in participants with advanced and,or refractory solid tumor malignancies
    Merck Sharp & Dohme LLC
  • A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
    Exelixis Inc.
  • A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
    Incyte Corporation
  • A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
    Exelixis Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Los Angeles

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 7, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1427317403. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.